TaiRx, Inc. engages in the research and development of novel drug products for cancer treatment. Its products include CVM-118, Rexis, Zelnite, TRX-711, TRX-NOC, TRX-920, and TRX-105. The company was founded by Du Shieng Chien and Yi Wen Chu on August 22, 2011 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company